MyofascialPainSyndrome:ATreatmentReview

Myofascial pain syndrome (MPS) is a common source of regional musculoskeletal pain, characterized by pain originating from hyperirritable spots called myofascial trigger points within taut bands of skeletal muscle. It frequently coexists with other pain conditions and poses significant challenges for clinicians due to the lack of specific diagnostic criteria and the elusive underlying pathology. Proper evaluation and management of myofascial pain are essential components of musculoskeletal rehabilitation. Despite its prevalence, there remains considerable debate about which treatments are most effective, and many interventions lack robust evidence specifically supporting their use in MPS.

The authors aimed to provide clinicians with a comprehensive, evidence-based overview of both pharmacologic and nonpharmacologic treatment options for this challenging condition.

The authors conducted an extensive literature search using PubMed, Ovid, and Google Scholar to identify relevant studies on treatments for myofascial pain. They prioritized controlled studies, followed by observational studies, and also included systematic reviews and Cochrane reviews. Non-English sources were excluded. Recognizing the considerable clinical overlap between MPS and related musculoskeletal disorders such as fibromyalgia, regional soft-tissue pain, craniomandibular dysfunction, and tension headache, the authors extrapolated evidence from these associated conditions when direct evidence for MPS was lacking.

For each treatment modality, they compiled relevant studies with stronger levels of evidence and generated clinical recommendations. They organized their findings into two major sections: pharmacologic treatments (including analgesics, muscle relaxants, anticonvulsants, antidepressants, botulinum toxin, and other agents) and nonpharmacologic treatments (including dry needling, trigger point injections, manual therapy, ultrasound, TENS, electrical twitch-obtaining intramuscular stimulation, magnetic stimulation, and laser therapy).

The review revealed that most interventions for MPS have a limited body of high-quality evidence supporting their use. Among pharmacologic treatments, no randomized controlled trials specifically evaluated oral NSAIDs for MPS, though a diclofenac patch showed statistically significant benefits for pain (P<0.01), cervical range of motion (P<0.01), and neck disability index (P=0.03). Tizanidine demonstrated significant decreases in pain intensity and disability from baseline (P<0.01) in an open-label study. Clonazepam showed statistically significant pain reduction (P<0.001) in an open clinical trial, but no RCTs exist.

Cyclobenzaprine showed statistically significant decrease in mean pain intensity compared to clonazepam (P=0.002), though a combination with ibuprofen showed no significant difference versus placebo plus ibuprofen (P=0.962). Topical thiocolchicoside demonstrated statistically significant improvement in pain severity (P<0.001) and range of motion in cervical myofascial pain. Lidocaine patches showed statistically significant increased pain thresholds (P<0.001) and increased general activity (P<0.05) across multiple studies. Botulinum toxin A showed mixed results: one multicenter RCT demonstrated statistically significant differences in pain intensity, duration, and reduction of trigger points (P=0.001), and a Cochrane review found one of four studies showed statistically significant decrease in pain intensity and duration (P<0.00001), yet other studies found no significant improvement versus placebo.

Ketamine showed no statistically significant benefit in one RCT. For nonpharmacologic treatments, dry needling and trigger point injections were supported as mainstays of interventional treatment, with one study showing dry needling superiority versus placebo in postsurgery analgesic demand (P=0.02) and visual analog scores at 1 month (P<0.04). A systematic review concluded that wet needling is not therapeutically superior to dry needling. Ultrasound showed mixed results: one meta-analysis found no documentation of effect, yet some individual RCTs showed statistically significant improvements in pain pressure threshold (P<0.002) and other outcomes.

TENS demonstrated significant pain reduction in several RCTs, with three of four modes showing significant reduction (P<0.001), though one study found no significant benefit over trigger point injections. Electrical twitch-obtaining intramuscular stimulation showed significant reduction in pain levels immediately after treatment sustained for 2 weeks (P<0.05) in a pilot study, and significant improvement in chronic refractory MPS (P<0.01). Magnetic stimulation showed statistically significant improvements in pain level (P<0.01) and range of motion (P<0.035) lasting 1 month versus placebo in one RCT, and longer-lasting benefits than TENS in another (P<0.05). Laser therapy showed the most contradictory evidence, with some RCTs demonstrating statistically significant pain reduction (P<0.05; P<0.01; P<0.002) while others found no significant benefit versus placebo.

For clinicians, this review highlights the critical importance of first identifying and addressing underlying causes of myofascial pain rather than focusing solely on symptomatic treatment. The heterogeneity of MPS and its overlap with central and peripheral neural mechanisms contributes to the difficulty in treating chronic cases. Among pharmacologic options, tizanidine, benzodiazepines, and tropisetron appear to have some limited evidence for use, while topical diclofenac and lidocaine patches may offer limited efficacy with favorable side effect profiles. NSAIDs and COX-2 inhibitors likely alleviate pain but require more controlled trials specifically in MPS.

For interventional treatments, dry needling and trigger point injections remain the mainstays, though sustainability depends on judicious use combined with manual therapies. Newer modalities such as ultrasound, TENS, and laser therapy show promise but require further research to establish clear evidence-based treatment algorithms. Patients should understand that MPS treatment often requires a multimodal approach, and that many commonly used treatments have limited high-quality evidence specifically supporting their use in this condition. The review underscores the need for well-designed, large-scale randomized controlled trials to better define optimal treatment strategies for myofascial pain syndrome.